OR WAIT null SECS
Few names in heart failure carry the same esteem as Scott Solomon, MD, of Brigham and Women’s Hospital. The director of the Clinical Trials Outcomes Center and Edward D. Frohlich Distinguished Chair at Harvard Medical School, Solomon has been an integral part of some of the most impactful advances in heart failure and cardiometabolic health in recent years, with Solomon playing a crucial role in landmark trials, including, but not limited to, DAPA-HF, DELIVER, PARAGON-HF, and more.
Management of heart failure, regardless of ejection fraction, has been substantially altered as a result of the research endeavors Solomon has led and participated in. Once thought to be a disease with few therapeutics options to confront the grim prognosis associated with diagnosis, heart failure specialists have been gifted with what some consider to be an embarrassment of riches in regard to newer therapies.
In recent years, major cardiology meetings, including the European Society of Cardiology, American College of Cardiology, and American Heart Association meetings, have served as the platform to broadcast results of these practice-altering trials and updated guidelines to those involved in management of heart failure and other cardiometabolic diseases.
With an interest in offering our audience a greater understanding of these trials and recent advances in the management of heart failure while on-site at AHA 22, The Heart Team, which is a multimedia series hosted by Michael Farkouh, MD, and Jorge Plutzky, MD, reached out to Solomon to take a deep dive into his experience in these trials, use of these medications, and what might be next for the heart failure community.